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Draft genomes of Shigella strains used 
by the STOPENTERICS consortium
Omar Rossi1†, Kate S Baker2†, Armelle Phalipon3, François‑Xavier Weill3, Francesco Citiulo1, Philippe Sansonetti3, 
Christiane Gerke1 and Nicholas R Thomson2*
Abstract 
Background: Despite a significant global burden of disease, there is still no vaccine against shigellosis widely avail‑
able. One aim of the European Union funded STOPENTERICS consortium is to develop vaccine candidates against 
Shigella. Given the importance of translational vaccine coverage, here we aimed to characterise the Shigella strains 
being used by the consortium by whole genome sequencing, and report on the stability of strains cultured in differ‑
ent laboratories or through serial passage.
Methods: We sequenced, de novo assembled and annotated 20 Shigella strains being used by the consortium. 
These comprised 16 different isolates belonging to 7 serotypes, and 4 derivative strains. Derivative strains from com‑
mon isolates were manipulated in different laboratories or had undergone multiple passages in the same laboratory. 
Strains were mapped against reference genomes to detect SNP variation and phylogenetic analysis was performed.
Results: The genomes assembled into similar total lengths (range 4.14–4.83 Mbp) and had similar numbers of pre‑
dicted coding sequences (average of 4,400). Mapping analysis showed the genetic stability of strains through serial 
passages and culturing in different laboratories, as well as varying levels of similarity to published reference genomes. 
Phylogenetic analysis revealed the presence of three main clades among the strains and published references, one 
containing the Shigella flexneri serotype 6 strains, a second containing the remaining S. flexneri serotypes and a third 
comprised of Shigella sonnei strains.
Conclusions: This work increases the number of the publically available Shigella genomes available and specifically 
provides information on strains being used for vaccine development by STOPENTERICS. It also provides information 
on the variability among strains maintained in different laboratories and through serial passage. This work will guide 
the selection of strains for further vaccine development.
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Background
Shigella are Gram-negative bacteria that represent the 
etiologic agent of the shigellosis, a global human health 
problem, especially in developing countries and in chil-
dren younger than 5  years. Shigellosis is estimated to 
cause annually 125 million cases and 100,000 deaths 
[1], and is one of main causes of traveller’s diarrhea. The 
genus Shigella comprises four serogroups (Shigella dys-
enteriae, Shigella sonnei, Shigella flexneri and Shigella 
boydii) subdivided in 50 different serotypes based on 
the carbohydrate composition of the O antigen of their 
lipopolysaccharide [2] and the presence of serotypes var-
ies among different regions and over time [3]. As no vac-
cines are currently widely available, one of the aims of the 
European Union-funded STOPENTERICS consortium 
(Vaccination against Shigella and ETEC: novel antigens, 
novel approaches) [4] is to develop novel vaccine candi-
dates against Shigella [e.g. the Generalized Modules for 
Membrane Antigens (GMMA) approach [5, 6]], as well as 
to improve the immunogenicity of the existing antigens 
(e.g. synthetic chemistry for glycoconjugates [7]). To this 
end, partners of the STOPENTERICS consortium have 
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been integrating basic research, particularly genomics, 
transcriptomics, proteomics, and other high-through-
put technologies, with novel vaccine technologies and 
synthetic chemistry [7]. To assemble Shigella expertise 
to identify and rapidly take novel vaccine candidates 
through to clinical trials for effective vaccine develop-
ment, the research is carried out among different aca-
demic institutions (e.g. University of Oxford, Wellcome 
Trust Sanger Institute, Institut Pasteur) and vaccines 
companies (Novartis Vaccines Institute for Global Health 
and Sanofi-Pasteur).
To ensure the congruence of strains between labora-
tories, and create a public resource for vaccine develop-
ment and further Shigella research, we whole genome 
sequenced the Shigella strains used by the STOPENTER-
ICS consortium which are used as they offer most effec-
tive breadth of cross-protection against Shigella sp. in 
endemic areas [8], and report the assembly and annota-
tion of their draft genomes. We assessed the presence of 
SNPs between strains and against references, as well as 
defined their phylogenetic relationships, and compared 
genetic stability of strains maintained in different consor-
tium laboratories and after serial passage.
Methods
Bacterial strains
The Shigella strains analysed in this study and relevant 
metadata are summarized in Table 1. Strains were sero-
typed by slide agglutination using commercially available 
monovalent antisera (Denka Seiken, Japan) to all type 
specific somatic antigens and the group factor antigens 
[9].
DNA extraction and genome sequencing
Bacterial cultures were grown over night in liquid Luria–
Bertani (LB) media to an optical density (measured at 
600 nm) of approximately three. Genomic DNA was iso-
lated using the Wizard kit (Promega, Madison, WI, USA) 
according to manufacturer’s instructions. Purified DNA 
was then sequenced at the Wellcome Trust Sanger Insti-
tute (WTSI). Paired end libraries 150 bp in length were 
generated and sequenced on the Illumina MiSeq instru-
ment (San Diego, CA, USA) according to in house pro-
tocols [10, 11], with an approximately 500 bp insert size. 
Sequence data for each of the strains were deposited in 
the European Nucleotide Archive (accession numbers in 
Table 1).
Genomic analysis
Resulting sequencing reads were trimmed using Trim-
momatic v0.27 [12] to remove adapters, bases with a 
PHRED score of <30, and remaining reads with lengths 
<50 bp.
High quality reads were then mapped to relevant refer-
ence strains (Table 1), using SMALT (http://www.sanger.
ac.uk/resources/software/smalt/) and Single Nucleotide 
Polymorphisms (SNPs) were called using Samtools [13]. 
Nucleotides where mapping quality was below 30 and 
genotyping quality was below 50 were excluded from 
further analysis. Mapping coverage of all isolates was 
approximately 70-fold coverage.
De novo assembly was performed using Velvet Opti-
miser [14] and contiguous sequences were annotated 
using Prokka [15]. Clustering and BLAST comparisons 
were used to determine the presence/absence of genes in 
annotated assemblies as previously described [16].
To prepare a multiple sequence alignment for phyloge-
netic analysis, sequencing data from strains in this study 
and from simulated fastq data created from published 
reference genomes were mapped to the chromosome of 
S. flexneri 2457T (GenBank accession: NC_004741.1). 
The other reference isolates (and their accessions) used 
in this analysis were: S. sonnei Ss046 (NC_007384.1), 
S. sonnei 53G (NC_016822.1), S. flexneri 5 M90T 
(AGNM01000000), S. flexneri 5a 8401 (NC_008258.1), 
S. flexneri 2a NCTC1 (LM651928), S. flexneri 2a 301 
(NC_004337.2), S. flexneri X 2002017 (NC_017328.1) and 
S. boydii Sb 227 (NC_007613.1). Core genes (n = 2,427) 
were identified that had 100% mapping coverage in all 
isolates and phylogenetic analysis was performed using 
RAxML software v7.0.3 [17] on the 43,349 variable sites 
(subset from 2,306,256 bp) of these core genes.
In silico molecular serotyping of S. flexneri isolates was 
performed on de novo assemblies for each isolate (and as 
in [18]). Briefly, the presence/absence and known differ-
ences of the gtr genes (encoding for enzymes responsible 
of the presence of type specific antigens I, II, IV, V, X, IC), 
oac genes (encoding for enzymes that mediates O-acet-
ylation modification in serotypes 1b, 3a, 3b, and 4b) 
and wzx6 (specific for serotype 6) were analyzed, facili-
tating the differentiation of the six different S. flexneri 
serotypes.
Results and discussion
Sixteen different Shigella isolates belonging to seven dif-
ferent serotypes were sequenced (listed in Table 1). These 
included S. sonnei (2 isolates) and different S. flexneri 
serotypes including 1a, 1b (2  isolates), 2a, 3a, 5a and 6 
(eight different isolates) plus four derivative strains from 
either serial passage (S. sonnei 53G, S. flexneri 2a 2457T) 
or having been cultivated and the DNA extracted in dif-
ferent laboratories (S.  flexneri 3a 6865 and S. flexneri 6 
10.5302). Derivative strains from the same isolate, but 
manipulated in different laboratories of the STOPEN-
TERICS consortium were denoted ‘_1’ and ‘_2’, whereas 
those that had undergone serial passage (~10 passages) 
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in the same laboratory were denoted ‘_p’. The derivatives 
allowed us to assess the genetic stability of strains across 
laboratories and through serial passage.
Results of genomic assembly and annotation were simi-
lar for all strains (Table 1). The strains assembled into an 
average of 381 contigs (range 265–446), with an average 
contigs length of 12,141  bp (range 9,897–15,619) and 
an N50 of 28,620 (range 22,494–35,991). The resulting 
genomic size was similar for all the strains and fell within 
the range of 4.14–4.83 Mbp. Similarly, automated anno-
tation predicted the presence of an average of 4,400 cod-
ing sequences per genome (range 4,044–4,583; Table 1). 
The serotypes of the Shigella strains were confirmed 
based on the combinations of gtr and oac genes, encod-
ing the relevant enzymes for the serotype-specific OAg 
modifications [18] (not shown).
To facilitate strain comparisons and phylogenetic anal-
ysis, sequence reads were mapped to existing Shigella 
reference genomes (Table 1). The percentage of the refer-
ence genome covered by mapped reads ranged from 87 
to 98% and the number of SNPs varied (Table 1) depend-
ing on the isolate. These data showed comparatively few 
SNPs (<200) when an isolate was compared to a previ-
ously published reference of itself (as in the case of S. 
sonnei 53G, S. flexneri 2a 2457T, S.  flexneri  5a M90T). 
Higher numbers of SNPs were seen where no such 
reference was available. For example, when an isolate was 
mapped to a reference genome of a different isolate of the 
same serotype (e.g. Ss_25931 mapped against Ss_53G) 
several hundred SNPs were seen, and several thousand 
SNPs were seen if the isolate was mapped to a reference 
isolate from a phylogenetic related, but distinct serotype 
(e.g. S. flexneri six isolates mapped against S. boydii strain 
Sb227).
To assess the genomic stability of isolates held at dif-
ferent laboratories and through serial passage within the 
same laboratory, we resequenced a number of isolates 
and compared their mapping results to the relevant ref-
erence (Table  1). Two isolates (original and passaged) 
of S. sonnei 53G had only two SNPs relative to the pub-
lished reference genome, and these SNPs were the same 
in both isolates. Similarly, the sequences of original and 
passaged S. flexneri 2a strain 2457T were very similar, 
but had 195 and 192 SNPs relative to the published ref-
erence genome. Among these SNPs, 188 were common 
to both isolates and the remaining four and seven sites 
were not resolved in the other isolate, indicating that the 
two isolates were likely identical to each other. The level 
of genetic variation compared to the reference strain was 
surprising (~200 SNPs) and may have biological signifi-
cance, showing the utility of obtaining up-to-date genetic 
information for the exact strain being worked with in a 
0.2
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Sf_6_NCDC.2924-71
Ss_25931
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Figure 1 Mid‑point rooted maximum likelihood phylogeny of strains based on core genome. Names of strains sequenced in this study are abbrevi‑
ated and those of reference genomes are given in full.
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given project. Two strains, Sf 3a_6865 and Sf 6_10.5302, 
were manipulated for sequencing in separate laboratories 
in the consortium. These strains differed by only one and 
two SNPs respectively, indicating that over a 2–3  year 
time period, isolate genomes remain relatively stable 
through passage and between laboratories, but may differ 
significantly from published references.
To assess the phylogenetic relationship of the isolates, 
we constructed a maximum likelihood phylogenetic tree 
of a large core genome shared among the strains (Fig-
ure 1). Consistent with expectations based on prior evo-
lutionary studies of shigellae [19, 20], the strains were 
divided into three main clades, with the S. flexneri six 
strains being phylogenetically removed from the remain-
ing S. flexneri serotypes, and the S. sonnei strains forming 
a separate clade.
Conclusions
The work presented here increases the number of publi-
cally available Shigella genomes, including for the first 
time, sequencing data for S. sonnei 25931, two S. flexneri 
1b, one S. flexneri 1a, one S. flexneri 3a and 8 S. flexneri 
six isolates. We provide details on the draft genomes gen-
erated from this sequencing data, and report SNP varia-
tion in strains maintained in different laboratories and 
after serial passage. We also described the relatedness of 
the strains and isolates used by the STOPENTERICS con-
sortium, and have deposited this data as a public resource. 
Data presented in this work will guide the selection of 
strains for further development of vaccine and contribute 
to a growing awareness of diversity in Shigella.
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